Seeking Alpha

OSI Pharmaceuticals (OSIP) moves up 1.1% as the FDA extends the review date of its lung cancer...

OSI Pharmaceuticals (OSIP) moves up 1.1% as the FDA extends the review date of its lung cancer drug Tarceva 90 days, to April 18.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)